Rani Therapeutics Board Restructures After DeBuono’s Retirement

Rani Therapeutics Holdings ( (RANI) ) has provided an update.

On April 24, 2025, Laureen DeBuono retired from the Board of Directors of Rani Therapeutics Holdings, Inc., with her decision not stemming from any disagreements with the company. Her departure led to a reconstitution of the Board’s committees, with new chairs and members appointed to the Audit, Compensation, and Nominating and Corporate Governance Committees.

Spark’s Take on RANI Stock

According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.

Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.

To see Spark’s full report on RANI stock, click here.

More about Rani Therapeutics Holdings

Rani Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on the development of oral biologics through its proprietary RaniPill capsule technology, which aims to replace injections with oral pills.

YTD Price Performance: -24.66%

Average Trading Volume: 871,348

Technical Sentiment Signal: Buy

Current Market Cap: $63.3M

For a thorough assessment of RANI stock, go to TipRanks’ Stock Analysis page.